

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8391220

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
CELLULAR BIOMEDICINE GROUP, INC.	11/15/2023
RECEIVING PARTY DATA	
Name:	ABELZETA INC.
Street Address:	9605 MEDICAL CENTER DRIVE
Internal Address:	SUITE 100
City:	ROCKVILLE
State/Country:	MARYLAND
Postal Code:	20850
PROPERTY NUMBERS Total: 17	
Property Type	Number
Patent Number:	11207349
Patent Number:	11439665
Patent Number:	11633430
Patent Number:	11066457
Patent Number:	11472858
Patent Number:	11618778
Patent Number:	11608369
Application Number:	17721647
Application Number:	17911502
Application Number:	17911524
Application Number:	18183681
Application Number:	17831637
Application Number:	18173187
Application Number:	18263050
Application Number:	63154032
Application Number:	63142216
Application Number:	63154040
CORRESPONDENCE DATA	

Fax Number: (617)607-9200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6174496512

Email: rlecesse@mccarter.com

Correspondent Name: MCCARTER & ENGLISH, LLP

Address Line 1: 265 FRANKLIN STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	137166-00001
--------------------------------	--------------

NAME OF SUBMITTER:	DYLAN M. BLUMENTHAL
---------------------------	---------------------

SIGNATURE:	/Dylan M. Blumenthal/
-------------------	-----------------------

DATE SIGNED:	01/19/2024
---------------------	------------

Total Attachments: 5

source=137166_00001_CertificateofAmendment_NameChangewithScheduleA#page1.tif

source=137166_00001_CertificateofAmendment_NameChangewithScheduleA#page2.tif

source=137166_00001_CertificateofAmendment_NameChangewithScheduleA#page3.tif

source=137166_00001_CertificateofAmendment_NameChangewithScheduleA#page4.tif

source=137166_00001_CertificateofAmendment_NameChangewithScheduleA#page5.tif

Delaware

The First State

Page 1

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "CELLULAR BIOMEDICINE GROUP, INC.", CHANGING ITS NAME FROM "CELLULAR BIOMEDICINE GROUP, INC." TO "ABELZETA INC.", FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF NOVEMBER, A.D. 2023, AT 9:17 O'CLOCK A.M.




Jeffrey W. Bullock, Secretary of State

5276825 8100
SR# 20233979237

You may verify this certificate online at corp.delaware.gov/authver.shtml

Authentication: 204595736
Date: 11-15-23

PATENT
REEL: 066356 FRAME: 0110

CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
CELLULAR BIOMEDICINE GROUP, INC.

Pursuant to Section 242 of the General
Corporation Law of the State of Delaware

Cellular Biomedicine Group, Inc., a Delaware corporation (hereinafter called the "Corporation"), does hereby certify as follows:

FIRST: Article ONE of the Corporation's Amended and Restated Certificate of Incorporation is hereby amended to read in its entirety as set forth below:

"The name of the corporation is AbelZeta Inc. (hereinafter called the "Corporation")."

SECOND: The foregoing amendment was duly adopted in accordance with Section 242 of the General Corporation Law of the State of Delaware.

State of Delaware
Secretary of State
Division of Corporations
Delivered 09:17 AM 11/15/2023
FILED 09:17 AM 11/15/2023
SR 20233979237 - File Number 5276825

PATENT
REEL: 066356 FRAME: 0111

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be duly executed in its corporate name this 15th day of November, 2023.

CELLULAR BIOMEDICINE GROUP, INC.

By: 
Name: Bizuo (Tony) Liu
Title: Chief Executive Officer

SCHEDULE A

McCarter Reference	Serial #	Filed Date	Patent #	Issue Date	Title
137166-00391	16/877,069	5/18/2020	11,207,349	12/28/2021	Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00301	63/154,032	2/26/2021			Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00302	17/475,766	9/15/2021	11,439,665	9/13/2022	Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00303	17/721,647	4/15/2022			Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00304	17/750,658	5/23/2022	11,633,430	4/25/2023	Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00305	17/911,502	9/14/2022			Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00306	17/911,524	9/14/2022			Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Applications Thereof
137166-00307	18/183,681	3/14/2023			Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof
137166-00400	16/484,482	8/8/2019	11,066,457	7/20/2021	Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00401	63/142,216	1/27/2021			Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00402	63/154,040	2/26/2021			Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof

137166-00403	17/352,915	6/21/2021	11,472,858	10/18/2022	Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00404	17/723,859	4/19/2022	11,618,778	4/4/2023	Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00405	17/750,855	5/23/2022	11,608,369	3/21/2023	Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00406	17/831,637	6/3/2022			Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00407	18/173,187	2/23/2023			Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
137166-00408	18/263,050	7/26/2023			Chimeric Antigen Receptors Targeting CD20